What are the recognition criteria and specific treatments for symptomatic bradycardia in the prehospital setting due to primary cardiac conduction disease, toxicologic causes, myocardial infarction (MI), and metabolic derangements?

Symptomatic Bradycardia in the Field: Recognition and Treatment by Etiology

For symptomatic bradycardia in the prehospital setting, immediately administer atropine 0.5 mg IV (up to 2 mg total) while simultaneously identifying the underlying cause, with transcutaneous pacing as backup for atropine-refractory cases—but recognize that atropine works best for AV nodal-level blocks and MI-related bradycardia, while it should be avoided in infranodal blocks and may be ineffective in toxicologic or severe metabolic causes. 1, 2

Initial Universal Approach

Regardless of suspected etiology, symptomatic bradycardia (HR <50 bpm with hypotension, altered mental status, chest pain, dyspnea, or syncope) requires immediate treatment 2:

• Atropine 0.5 mg IV boluses every 5 minutes, maximum 2 mg total 1, 3
• Apply transcutaneous pacing patches immediately as standby 1, 2
• Address hypoxia and support airway/breathing—hypoxia is associated with pacing failure and increased mortality 2

Critical Atropine Pitfall

Never give <0.5 mg doses—this causes paradoxical bradycardia through peripheral parasympathomimetic effects 3. The peak effect occurs within 3 minutes 3.

---

Recognition and Specific Treatment by Etiology

1. Primary Cardiac Conduction Disease

Recognition:

• Narrow-complex escape rhythm = AV nodal level block (2nd degree Type I, 3rd degree with narrow QRS) 1
• Wide-complex escape rhythm = infranodal block (usually anterior MI with 2nd degree Type II or 3rd degree with wide QRS) 1
• New bifascicular block (RBBB + LAFB/LPFB) or LBBB 1
• Recurrent sinus pauses >3 seconds 1
• History of syncope without clear precipitant 4

Specific Treatment:

• AV nodal level blocks (narrow complex): Atropine is effective and indicated 1, 3
• Infranodal blocks (wide complex): Atropine is contraindicated (Class III)—proceed directly to transcutaneous pacing 1
• Mobitz Type II or new bundle branch blocks: Transcutaneous pacing is Class II indication; prepare for transvenous pacing 1

Key Distinction: The width of the escape rhythm determines atropine appropriateness—narrow = use atropine, wide = skip to pacing 1.

---

2. Myocardial Infarction (MI)

Recognition:

• Inferior MI pattern (II, III, aVF ST elevation) with bradycardia—most common, occurs within 6 hours of symptom onset 1
• Chest pain with bradycardia and hypotension 5, 6
• Bezold-Jarisch reflex (vagal surge from reperfusion, especially right coronary artery) 1
• Bradycardia following nitroglycerin or morphine administration 1
• Anterior MI with wide-complex bradycardia = infranodal block, high-risk 1

Specific Treatment:

• Atropine is most effective for MI-related bradycardia within first 6 hours 1
• Dose: 0.5 mg increments to achieve ~60 bpm (not higher—excessive tachycardia increases ischemia) 1
• Use atropine cautiously—parasympathetic tone protects against VF and infarct extension 1
• In bradycardia-hypotension syndrome: atropine increases HR from 46±14 to 79±12 bpm and SBP from 70±15 to 105±13 mmHg 6
• Inferior MI with 2nd degree Type I block: Atropine is Class I 3
• Anterior MI with wide-complex escape: Skip atropine, use transcutaneous pacing 1

Critical Point: 55.6% of patients presenting with hemodynamically unstable AV block have acute MI 5—obtain 12-lead ECG immediately and activate catheterization lab if STEMI criteria met.

---

3. Toxicologic Causes

Recognition:

• Beta-blockers: Bradycardia + hypotension + altered mental status, possible bronchospasm
• Calcium channel blockers: Bradycardia + profound hypotension (worse than beta-blockers), hyperglycemia
• Digoxin: Bradycardia + AV block + visual changes (yellow halos), nausea, any dysrhythmia possible
• Opioids: Bradycardia + respiratory depression + miosis (pinpoint pupils)
• Organophosphates: Bradycardia + SLUDGE syndrome (salivation, lacrimation, urination, defecation, GI distress, emesis) + miosis
• Clonidine/alpha-2 agonists: Bradycardia + hypotension + altered mental status

Specific Treatment:

Atropine has limited efficacy for most toxicologic bradycardias—it may temporarily increase rate but doesn't address the underlying receptor blockade or toxicity.

• Beta-blocker overdose:

  • Glucagon 3-5 mg IV bolus (bypasses beta-receptors)
  • High-dose insulin euglycemic therapy (1 unit/kg bolus, then 1 unit/kg/hr infusion with dextrose)
  • Transcutaneous pacing if refractory

• Calcium channel blocker overdose:

  • Calcium chloride 10-20 mL of 10% solution IV (or calcium gluconate 30-60 mL of 10%)
  • High-dose insulin euglycemic therapy (same dosing as beta-blocker)
  • Transcutaneous pacing often ineffective due to lack of myocardial contractility

• Digoxin toxicity:

  • Digoxin-specific antibody fragments (DigiFab) for life-threatening toxicity
  • Atropine may worsen ventricular arrhythmias—use cautiously
  • Avoid calcium (increases digoxin binding to myocardium)

• Opioid overdose:

  • Naloxone 0.4-2 mg IV/IM/IN (ECG-to-intervention time: 1 minute) 7
  • Bradycardia typically resolves with reversal of respiratory depression

• Organophosphate poisoning:

  • Atropine 2-5 mg IV (much higher doses than for bradycardia alone), repeat every 5 minutes until secretions dry
  • Pralidoxime 1-2 g IV over 30 minutes

Prehospital Priority: For suspected toxic ingestions, atropine may provide temporary bridge, but definitive antidote administration is critical and should not be delayed.

---

4. Metabolic Derangements

Recognition:

• Hyperkalemia: Peaked T waves → widened QRS → sine wave pattern, often with renal failure history
• Severe hypothyroidism (myxedema coma): Bradycardia + hypothermia + altered mental status + delayed reflexes + periorbital edema
• Hypothermia: Core temperature <35°C, J waves (Osborn waves), bradycardia proportional to temperature
• Severe acidosis: pH <7.1, bradycardia with other signs of shock
• Hypoxia: SpO2 <90%, bradycardia as pre-terminal sign

Specific Treatment:

Atropine is generally ineffective for metabolic causes—treat the underlying metabolic derangement.

• Hyperkalemia (ECG changes present):

  • Calcium chloride 10 mL of 10% solution IV over 2-5 minutes (membrane stabilization, works in 1-3 minutes) 7
  • Note: ECG-to-calcium time averaged 111 minutes in one study—this is too slow 7
  • Sodium bicarbonate 50 mEq IV if concurrent acidosis
  • Insulin 10 units IV + dextrose 25 g (D50W 50 mL)
  • Albuterol 10-20 mg nebulized
  • Transcutaneous pacing often ineffective until potassium lowered

• Severe hypothyroidism:

  • Levothyroxine 200-400 mcg IV loading dose
  • Hydrocortisone 100 mg IV (treat possible concurrent adrenal insufficiency)
  • Passive rewarming, supportive care
  • Atropine typically ineffective

• Hypothermia:

  • Active rewarming is definitive treatment
  • Environmental hypothermia: ECG-to-warming 26 minutes 7
  • Hypothermic sepsis: ECG-to-warming 112 minutes (too slow) 7
  • Atropine and pacing often ineffective until core temperature >30°C
  • Warm IV fluids, remove wet clothing, active external rewarming

• Severe acidosis:

  • Treat underlying cause (sepsis, DKA, lactic acidosis)
  • Sodium bicarbonate if pH <7.1 and hemodynamically unstable
  • Atropine unlikely to work until pH improves

• Hypoxia:

  • 100% oxygen, support ventilation
  • Hypoxia is associated with transcutaneous pacing failure 2
  • Bradycardia from hypoxia is pre-arrest—aggressive airway management required

---

Transcutaneous Pacing: When and How

Indications for immediate pacing 1, 2:

• Symptomatic bradycardia unresponsive to atropine (SBP <80 mmHg despite 2 mg atropine) 1
• Infranodal AV block (wide-complex escape rhythm) 1
• Mobitz Type II or 3rd degree AV block with hemodynamic compromise 1
• New bifascicular block with symptoms 1

Pacing Technique:

• Apply patches immediately as standby in all symptomatic bradycardia 1, 2
• Start at 60-80 bpm, increase output until electrical and mechanical capture
• Requires sedation in conscious patients (painful) 2
• Pacing is a bridge to transvenous pacing or definitive treatment 1

Pacing Limitations:

• No survival benefit in bradyasystolic cardiac arrest (0/215 survived in case series) 8
• Limited evidence for symptomatic bradycardia (5/6 paced vs 1/7 control survived in one trial) 8
• Often ineffective in severe toxicologic or metabolic causes until underlying problem addressed

---

Common Pitfalls to Avoid

1. Giving atropine for wide-complex bradycardia/infranodal block—this is Class III (contraindicated) 1
2. Doses <0.5 mg—causes paradoxical slowing 3
3. Over-relying on atropine for toxicologic causes—give specific antidotes 7
4. Delaying calcium for hyperkalemia with ECG changes—should be <5 minutes, not 111 minutes 7
5. Attempting cardioversion for atrial fibrillation with slow ventricular response—this represents complete AV block requiring pacing 7
6. Using atropine in acute MI to achieve excessive tachycardia—titrate to ~60 bpm only, as tachycardia worsens ischemia 1
7. Failing to address hypoxia first—hypoxia predicts pacing failure and mortality 2

---

Algorithmic Summary

Step 1: Identify symptomatic bradycardia (HR <50 + hypotension/altered mental status/chest pain/dyspnea)

Step 2: Apply transcutaneous pacing patches as standby + ensure adequate oxygenation

Step 3: Determine etiology and rhythm characteristics:

• Narrow-complex escape OR inferior MI → Atropine 0.5 mg IV (repeat q5min to 2 mg max)
• Wide-complex escape OR anterior MI → Skip atropine, activate pacing
• Suspected toxin → Give specific antidote (naloxone/calcium/glucagon/DigiFab)
• Hyperkalemia with ECG changes → Calcium chloride 10 mL IV immediately
• Hypothermia → Active rewarming
• Hypoxia → Aggressive oxygenation/ventilation

Step 4: If atropine fails or contraindicated → Transcutaneous pacing at 60-80 bpm

Step 5: Transport to facility capable of transvenous pacing and definitive management

The response to atropine occurs within 1-3 minutes 3, 9—if no improvement by then, proceed to next intervention rather than waiting. Approximately 50% of prehospital patients with symptomatic bradycardia respond partially or completely to atropine 9, with better response in sinus/junctional bradycardia (single dose often sufficient) compared to AV block (requires higher total doses) 9, 5.